Detalhe da pesquisa
1.
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Blood
; 127(4): 411-9, 2016 Jan 28.
Artigo
Inglês
| MEDLINE | ID: mdl-26542378
2.
Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin.
Protein Expr Purif
; 88(1): 157-63, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23291225
3.
Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.
Mol Cancer
; 10: 147, 2011 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-22168338
4.
Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Mol Pharmacol
; 76(5): 984-91, 2009 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-19657047
5.
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Breast Cancer Res
; 11(5): R73, 2009.
Artigo
Inglês
| MEDLINE | ID: mdl-19811637
6.
The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Cancer Res
; 68(7): 2358-65, 2008 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18381443
7.
huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.
Cancer Immunol Immunother
; 56(4): 447-57, 2007 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-16874486